预测局部晚期直肠癌术前同步放化疗敏感性的生物学指标

Biological indexes for predicting sensitivity of preoperative concurrent chemoradiotherapy for locally advancedrectalcancer

局部晚期直肠癌术前同步放化疗后肿瘤降期明显,可提高保肛率及局部控制率,不良反应可耐受,但临床疗效个体差异大。近年来研究发现,环氧合酶-2、G蛋白偶联受体、P53结合蛋白1、纤维蛋白原/白蛋白比值、程序性细胞死亡因子4、肿瘤浸润淋巴细胞、微小RNA等生物学指标与局部晚期直肠癌新辅助治疗的敏感性相关,可预测术前同步放化疗的敏感性。

After the preoperative concurrent chemoradiotherapy for local advanced rectal cancer,the down-staging of tumor is obvious,the rate of anal preservation and the local control rate are improved,and the side reactions are acceptable,but the individual clinical efficacy varies greatly.Recent studies have found that cyclooxygenase-2,G protein coupled receptor,P53 binding protein 1,fibrinogen-to-albumin ratio,programmed cell death factor 4,tumor infiltrating lymphocytes,microRNA are related to the sensitivity of neoadjuvant therapy for locally advanced rectal cancer,which can predict the sensitivity of preoperative concurrent chemoradiotherapy.